Generic Name and Formulations:
Methyldopa 125mg, 250mg, 500mg; tabs.
Various generic manufacturers
Indications for Methyldopa:
Initially 250mg 2–3 times daily; titrate at intervals of at least 2 days. Concomitant antihypertensives other than thiazides: initial max 500mg/day. Maintenance: 500mg–2g/day in 2–4 divided doses; max 3g/day.
Initially 10mg/kg per day in 2–4 divided doses; max 65mg/kg or 3g daily (whichever is less).
Active hepatic disease. History of methyldopa-associated liver dysfunction. Concomitant MAOIs.
Hepatic or renal dysfunction. Pheochromocytoma. Severe cerebrovascular disease. Monitor blood and liver function. Discontinue if fever, jaundice, liver dysfunction, worsening edema or heart failure occurs. Surgery. Pregnancy (Cat.B). Nursing mothers.
Central alpha agonist.
MAOIs: see Contraindications. Antagonized by oral iron preps: not recommended. May potentiate antihypertensives, general anesthetics, lithium. May interfere with lab tests.
Sedation, headache, asthenia, orthostatic hypotension, bradycardia, edema, GI upset, rash, nasal congestion, arthralgia, amenorrhea, hyperprolactinemia, gynecomastia, pancreatitis, impotence, decreased libido, CNS effects, eosinophilia, liver dysfunction, jaundice, (+) Coombs test, hemolytic anemia; rarely: fatal hepatic necrosis, blood dyscrasias.
Formerly known under the brand name Aldomet.
Clinical Pain Advisor Articles
- Opioid Use Disorders: Advances in Pharmacotherapy Provide Long-term Results
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- FDA Taps Social Media to Identify and Assess Emerging Drug Abuse Threats
- Buffered Lidocaine May Be Superior to Nonbuffered Lidocaine for Inferior Alveolar Nerve Block
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Marijuana's Uncertain Status: Closing the Gap Between State and Federal Policies